Medicaid
4 articles on Medicaid, written by Shotlee and medically reviewed for clinical accuracy.
Medicaid GLP-1 Coverage Changes: Access to Ozempic and Wegovy
A growing number of state Medicaid programs are restricting or eliminating coverage for GLP-1 medications like Ozempic and Wegovy for obesity treatment due to budget constraints.
8 min read
CMS Introduces Initiative to Enhance GLP-1 Availability in Medicaid and Medicare Part D
A novel CMS demonstration program seeks to broaden access to GLP-1 receptor agonists for individuals in Medicare Part D and Medicaid, aiming to address weight management and metabolic health. While it promises negotiations with manufacturers for reduced prices, experts remain skeptical about its widespread effectiveness. The initiative builds on prior drug pricing efforts and includes provisions for lifestyle support, with launch timelines set for 2026.
5 min read
Healthcare Costs in 2026: Some Will Pay More, Others Less
The healthcare landscape will undergo significant changes in 2026. Negotiated Medicare drug prices offer relief to some, but the expiration of Affordable Care Act tax credits and Medicaid uncertainties will increase costs for others.
6 min read
GLP-1 Restrictions: What Michigan's Medicaid Changes Mean for You
Michigan is tightening access to GLP-1 drugs like Ozempic and Wegovy for weight loss under Medicaid. This blog post explains the changes, explores the impact on patients, and discusses alternative approaches to weight management and metabolic health.
4 min read